Compare YieldMax COIN Option Income Strategy ETF (CONY) vs Quest Diagnostics Inc (DGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax COIN Option Income Strategy ETF vs Quest Diagnostics Inc — how do they compare? YieldMax COIN Option Income Strategy ETF trades at $20.4, while Quest Diagnostics Inc trades at $202.3 (market cap $22.80B). The key difference: Quest Diagnostics Inc pays a 1.67% dividend while YieldMax COIN Option Income Strategy ETF pays none, and Quest Diagnostics Inc is trading nearer its 52-week high, YieldMax COIN Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| CONY | DGX | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $103.20 | $216.02 |
52-Week Low | $18.43 | $166.42 |
Market Cap | — | $22.80B |
Enterprise Value | — | $28.82B |
Dividend Yield | — | 1.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CONY trades at $19.46, down 0.87% on the day, with a bearish technical signal from moving averages and neutral oscillators. The ETF has paid consistent weekly dividends, with recent payouts ranging from $0.24 to $0.56 per share. Key support lies at $19, with resistance at $20. Recent news highlights YieldMax's weekly distribution announcements, but some articles express concern over the ETF's long-term performance despite its high yield.
The outlook for CONY hinges on its ability to sustain high distributions through options strategies on Coinbase stock. Risks include the underlying volatility of Coinbase and the potential for distribution cuts if option income declines. Investors should weigh the attractive yield against the fund's bearish price trend and dependence on a single stock's options market.
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About YieldMax COIN Option Income Strategy ETF
CONY is an actively managed ETF that seeks to generate weekly income by selling call options on Coinbase (COIN) stock. It aims to provide high yield while maintaining exposure to the price movements of the crypto exchange.
Read more on CONY →About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →
